Experimental drug aims to supercharge radiation against glioblastoma

NCT ID NCT06359379

Terminated Disease control Sponsor: Shuttle Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tested a drug called ropidoxuridine, taken as a pill, to see if it could make radiation therapy more effective for people with a newly diagnosed, aggressive type of brain cancer (glioblastoma). The study enrolled 30 patients with a specific genetic marker (unmethylated MGMT promoter). Unfortunately, the trial was terminated early, so we have limited data on whether the drug helps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ropidoxuridine
What this could lead to: If it worked, this could point toward a way to make radiation more effective against a tough brain cancer.
What could go wrong: This trial was terminated early, so results are limited. It was a small Phase 2 study, and the drug may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA, IDH-WILDTYPE

Contacts and locations

Locations

Allegheny General Hospital

Pittsburgh, Pennsylvania, 15212, United States
John Theurer Cancer Center at the Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, 20007, United States
Miami Cancer Institute

Miami, Florida, 33176, United States
University of Virginia

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.